AC Immune's NLRP3 Inhibitor ACI-19764 Shows Promising Early Safety Data
Event summary
- AC Immune's Phase 1 trial for ACI-19764, an orally available NLRP3 inhibitor, showed positive preliminary safety and tolerability data across single and multiple ascending dose cohorts.
- The therapeutic dose is expected to be ≤10mg once daily based on pharmacokinetic (PK) data.
- The trial has commenced dosing of a cardiovascular risk cohort, with initial results expected by year-end 2026.
- Full results from the Phase 1/1b trial are anticipated in H1 2027.
The big picture
AC Immune's positive preliminary data for ACI-19764 comes at a time when NLRP3 inhibitors are gaining traction as a promising modality for treating chronic inflammation associated with neurodegenerative and metabolic diseases. The company's ability to demonstrate efficacy in the cardiovascular risk cohort could position ACI-19764 as a transformational treatment option, potentially expanding its therapeutic applications beyond neurodegenerative diseases.
What we're watching
- Clinical Efficacy
- How the anti-inflammatory activity of ACI-19764 will manifest in the cardiovascular risk cohort and whether it will meet expectations by year-end.
- Market Positioning
- Whether AC Immune can leverage these results to strengthen its position in the growing NLRP3 inhibitor market.
- Regulatory Pathway
- The pace at which AC Immune can advance ACI-19764 through subsequent clinical phases based on the Phase 1/1b trial results.
Related topics